NCT03074513 2026-03-11
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
21 trialsNCT05525767 2025-12-11
Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer
Hebei Medical University Fourth Hospital
Phase 4 Recruiting
NCT06576037 2025-10-15
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06139211 2024-12-20
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Recruiting
NCT03654833 2023-03-14
MiST
University of Leicester
Phase 2 Unknown
NCT05035381 2021-09-05
PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT00786669 2021-02-10
VITAC
Children's Hospital Medical Center, Cincinnati
Phase 1 Completed
NCT00295503 2020-10-20
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT02857920 2020-09-14
Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors
Fuda Cancer Hospital, Guangzhou
Phase 1/2 Completed
NCT00390156 2020-07-28
Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors
University of California, San Francisco
Phase 1 Completed
NCT00604461 2017-03-23
Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT00416637 2016-07-07
Bevacizumab in Treating Patients With Advanced Solid Tumors
Duke University
Phase 1 Completed
NCT02446431 2015-05-18
Metronomic
Miller Children's & Women's Hospital Long Beach
Phase EARLY_PHASE1 Recruiting
NCT00888043 2015-03-11
CNTO95/Avastin
Duke University
Phase 1 Completed
NCT00276575 2014-11-19
Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors
Duke University
Phase 1 Completed
NCT00586443 2014-11-19
BEP
Duke University
Phase 1 Completed
NCT00586092 2013-04-08
A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors
Duke University
Phase 1 Completed
NCT01055795 2012-12-24
BEL
Duke University
Phase 1 Completed
NCT00137826 2011-12-26
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00407459 2011-09-02
Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma
Istituto Clinico Humanitas
Phase 2 Completed
NCT00556088 2010-12-30
LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed